Galmed Pharmaceuticals (GLMD) Stock Rating Lowered by ValuEngine
ValuEngine cut shares of Galmed Pharmaceuticals (NASDAQ:GLMD) from a sell rating to a strong sell rating in a research report report published on Wednesday.
GLMD has been the topic of a number of other reports. Maxim Group set a $14.00 target price on shares of Galmed Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, January 3rd. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a hold rating to a buy rating and set a $8.50 target price on the stock in a research note on Tuesday, November 14th. Roth Capital initiated coverage on shares of Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They issued a buy rating and a $32.00 target price on the stock. Finally, HC Wainwright reissued a buy rating and set a $18.00 price target on shares of Galmed Pharmaceuticals in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $20.40.
Shares of Galmed Pharmaceuticals (NASDAQ GLMD) traded up $0.16 on Wednesday, reaching $5.43. 23,060 shares of the company were exchanged, compared to its average volume of 112,955. The stock has a market capitalization of $84.42, a P/E ratio of -4.45 and a beta of 2.90. Galmed Pharmaceuticals has a 1-year low of $3.61 and a 1-year high of $12.22.
ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/galmed-pharmaceuticals-glmd-stock-rating-lowered-by-valuengine/1905360.html.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.